330 related articles for article (PubMed ID: 31900160)
1. Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma.
Voigtländer T; Metzger J; Husi H; Kirstein MM; Pejchinovski M; Latosinska A; Frantzi M; Mullen W; Book T; Mischak H; Manns MP
J Biomed Sci; 2020 Jan; 27(1):13. PubMed ID: 31900160
[TBL] [Abstract][Full Text] [Related]
2. Urine proteomics study reveals potential biomarkers for the differential diagnosis of cholangiocarcinoma and periductal fibrosis.
Duangkumpha K; Stoll T; Phetcharaburanin J; Yongvanit P; Thanan R; Techasen A; Namwat N; Khuntikeo N; Chamadol N; Roytrakul S; Mulvenna J; Mohamed A; Shah AK; Hill MM; Loilome W
PLoS One; 2019; 14(8):e0221024. PubMed ID: 31425520
[TBL] [Abstract][Full Text] [Related]
3. Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker.
Chiang KC; Yeh TS; Wu RC; Pang JS; Cheng CT; Wang SY; Juang HH; Yeh CN
Sci Rep; 2016 Oct; 6():36138. PubMed ID: 27782193
[TBL] [Abstract][Full Text] [Related]
4. Novel Potential Biomarkers for
Aksorn N; Roytrakul S; Kittisenachai S; Leelawat K; Chanvorachote P; Topanurak S; Hamano S; Lek-Uthai U
In Vivo; 2018; 32(4):871-878. PubMed ID: 29936472
[TBL] [Abstract][Full Text] [Related]
5. A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of cholangiocarcinoma.
Shi Y; Deng X; Zhan Q; Shen B; Jin X; Zhu Z; Chen H; Li H; Peng C
J Gastrointest Surg; 2013 Sep; 17(9):1584-91. PubMed ID: 23868055
[TBL] [Abstract][Full Text] [Related]
6. Current omics-based biomarkers for cholangiocarcinoma.
Intuyod K; Armartmuntree N; Jusakul A; Sakonsinsiri C; Thanan R; Pinlaor S
Expert Rev Mol Diagn; 2019 Nov; 19(11):997-1005. PubMed ID: 31566016
[No Abstract] [Full Text] [Related]
7. Identification of TPD52 and DNAJB1 as two novel bile biomarkers for cholangiocarcinoma by iTRAQ‑based quantitative proteomics analysis.
Ren H; Luo M; Chen J; Zhou Y; Li X; Zhan Y; Shen D; Chen B
Oncol Rep; 2019 Dec; 42(6):2622-2634. PubMed ID: 31661142
[TBL] [Abstract][Full Text] [Related]
8. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
Rimassa L; Personeni N; Aghemo A; Lleo A
J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
[TBL] [Abstract][Full Text] [Related]
9. Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring.
Wen N; Peng D; Xiong X; Liu G; Nie G; Wang Y; Xu J; Wang S; Yang S; Tian Y; Li B; Lu J; Cheng N
Signal Transduct Target Ther; 2024 May; 9(1):107. PubMed ID: 38697972
[TBL] [Abstract][Full Text] [Related]
10. Targeting cholangiocarcinoma.
Mertens JC; Ilyas SI; Gores GJ
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
[TBL] [Abstract][Full Text] [Related]
11. Proteomics-based identification of α-enolase as a potential prognostic marker in cholangiocarcinoma.
Yonglitthipagon P; Pairojkul C; Bhudhisawasdi V; Mulvenna J; Loukas A; Sripa B
Clin Biochem; 2012 Jul; 45(10-11):827-34. PubMed ID: 22552009
[TBL] [Abstract][Full Text] [Related]
12. miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma.
Puik JR; Meijer LL; Le Large TY; Prado MM; Frampton AE; Kazemier G; Giovannetti E
Pharmacogenomics; 2017 Sep; 18(14):1343-1358. PubMed ID: 28832247
[TBL] [Abstract][Full Text] [Related]
13. Serum and bile biomarkers for cholangiocarcinoma.
Alvaro D
Curr Opin Gastroenterol; 2009 May; 25(3):279-84. PubMed ID: 19396965
[TBL] [Abstract][Full Text] [Related]
14. Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma.
Sriwanitchrak P; Viyanant V; Chaijaroenkul W; Srivatanakul P; Gram HR; Eursiddhichai V; Na-Bangchang K
Asian Pac J Cancer Prev; 2011; 12(6):1503-10. PubMed ID: 22126489
[TBL] [Abstract][Full Text] [Related]
15. Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma.
Song WS; Park HM; Ha JM; Shin SG; Park HG; Kim J; Zhang T; Ahn DH; Kim SM; Yang YH; Jeong JH; Theberge AB; Kim BG; Lee JK; Kim YG
Sci Rep; 2018 Jul; 8(1):11088. PubMed ID: 30038332
[TBL] [Abstract][Full Text] [Related]
16. Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy.
Sharif AW; Williams HR; Lampejo T; Khan SA; Bansi DS; Westaby D; Thillainayagam AV; Thomas HC; Cox IJ; Taylor-Robinson SD
HPB (Oxford); 2010 Aug; 12(6):396-402. PubMed ID: 20662790
[TBL] [Abstract][Full Text] [Related]
17. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
Wu HJ; Chu PY
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
[TBL] [Abstract][Full Text] [Related]
18. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
[TBL] [Abstract][Full Text] [Related]
19. Utility of Claudin-3 in extracellular vesicles from human bile as biomarkers of cholangiocarcinoma.
Ikeda C; Haga H; Makino N; Inuzuka T; Kurimoto A; Ueda T; Matsuda A; Kakizaki Y; Ishizawa T; Kobayashi T; Sugahara S; Tsunoda M; Suda K; Ueno Y
Sci Rep; 2021 Jan; 11(1):1195. PubMed ID: 33441949
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients.
Cavalloni G; Peraldo-Neia C; Massa A; Bergamini C; Trentini A; De Rosa G; Daniele L; Ciccosanti F; Cervellati C; Leone F; Aglietta M
BMC Cancer; 2021 Jul; 21(1):865. PubMed ID: 34320944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
